1. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 study group;Aapro;Semin. Oncol.,1998
2. A single-arm phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2- positive advanced breast cancer (PERUSE);Bachelot;Cancer Res.,2012
3. First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE;Bachelot;J. Clin. Oncol.,2014
4. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data;Bidard;Lancet Oncol.,2014
5. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes;Blum;Clin. Breast Cancer,2007